{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:47Z","timestamp":1792718327807,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This academic, multicenter, double-blind, noncomparative randomized clinical trial was conducted at 4 dermatology departments between July 2021 and April 2023 and included adult patients with extensive and active nonsegmental vitiligo. The study was designed to evaluate the effect of baricitinib plus narrowband UV-B based solely on the results from this experimental group. The placebo group was used as a calibration group. Data were analyzed from August to November 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants were randomized 3:1 to baricitinib, 4 mg per day, or placebo for 36 weeks alone for the first 12 weeks and then in combination with narrowband UV-B twice a week from weeks 12 to 36.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was mean percentage change in total Vitiligo Area Scoring Index (VASI) score from baseline to week 36 (baricitinib group). The prespecified aim of the study was to show that the reduction in the baricitinib plus narrowband UV-B was significantly greater than 42.9%, a repigmented surface threshold previously observed in patients treated with narrowband UV-B alone. Adverse events and secondary outcomes of change in disease activity and QOL were assessed. Post hoc analyses were additionally performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 49 included patients, 35 (71%) were female, and the median (IQR) age was 49.9 (38.4-59.8) years. A total of 37 patients were randomized to the baricitinib group and 12 to the placebo group. The mean change in total VASI at week 36 was \u221244.8% (95% CI, \u221258.4% to \u221231.3%) for the baricitinib group and \u22129.2% (95% CI, \u221227.7% to 24.7%) for the placebo group. This was not significantly greater than the sufficient repigmented surface threshold of 42.9%. Post hoc analyses showed a significant difference at week 36 for total VASI score in the baricitinib plus narrowband UV-B group compared with placebo plus narrowband UV-B (\u221244.8% vs \u22129.2%, respectively; <jats:italic>P<\/jats:italic>\u2009=\u2009.02). There was a greater improvement in disease activity and QOL in the baricitinib group vs placebo group and no significant difference in the number of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This proof-of-concept randomized clinical trial confirmed the efficacy of baricitinib combined with narrowband UV-B in the treatment of patients with extensive and active vitiligo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04822584\">NCT04822584<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5737","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T16:33:26Z","timestamp":1737563606000},"page":"375","source":"Crossref","is-referenced-by-count":34,"title":["Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo"],"prefix":"10.1001","volume":"161","author":[{"given":"Julien","family":"Seneschal","sequence":"first","affiliation":[{"name":"CHU de Bordeaux, Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, H\u00f4pital Saint-Andr\u00e9, UMR 5164, Bordeaux, France"},{"name":"CNRS, Immuno ConcEpT, UMR 5164, University Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Guyon","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, H\u00f4pital Saint-Andr\u00e9, UMR 5164, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ribal","family":"Merhi","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, H\u00f4pital Saint-Andr\u00e9, UMR 5164, Bordeaux, France"},{"name":"CNRS, Immuno ConcEpT, UMR 5164, University Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Mazereeuw-Hautier","sequence":"additional","affiliation":[{"name":"CHU Toulouse, National Reference Center for Rare Skin Diseases, Department of Dermatology, H\u00f4pital Larrey, CHU Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andreu","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, H\u00f4pital Saint-Andr\u00e9, UMR 5164, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cazenave","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, H\u00f4pital Saint-Andr\u00e9, UMR 5164, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Department of Dermatology, AP-HP, Henri Mondor University Hospital, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics\u2014EA 7379, Universit\u00e9 Paris-Est Cr\u00e9teil, INSERM, Clinical Investigation Centre 1430, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, Centre Hospitalier Universitaire de Nice, Department of Dermatology, Nice, France"},{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, INSERM U1065, C3M, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[{"name":"CNRS, Immuno ConcEpT, UMR 5164, University Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi240069r1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy.","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"doi240069r2","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo.","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"doi240069r3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review.","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"doi240069r4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study.","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"9","key":"doi240069r5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","article-title":"The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes.","volume":"36","author":"Picardo","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi240069r6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, from physiopathology to emerging treatments: a review.","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi240069r7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo.","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"doi240069r8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on vitiligo pathogenesis.","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"doi240069r9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3.","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi240069r10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo.","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi240069r11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin.","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"issue":"11","key":"doi240069r12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133772","article-title":"Type-1 cytokines regulate matrix metalloprotease-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"doi240069r13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling.","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi240069r14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/bjd.18902","article-title":"Phenotype and function of circulating memory T cells in human vitiligo.","volume":"183","author":"Martins","year":"2020","journal-title":"Br J Dermatol"},{"issue":"610","key":"doi240069r15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8995","article-title":"scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function.","volume":"13","author":"Gellatly","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"doi240069r16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cells12020217","article-title":"Pathogenic Th2 cytokine profile skewing by IFN-?-responding vitiligo fibroblasts via CCL2\/CCL8.","volume":"12","author":"Jin","year":"2023","journal-title":"Cells"},{"issue":"450","key":"doi240069r17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"doi240069r18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","article-title":"Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo.","volume":"139","author":"Chen","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"doi240069r19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jaci.2023.11.017","article-title":"Resident memory T cells in nonlesional skin and healed lesions of patients with chronic inflammatory diseases: appearances can be deceptive.","volume":"153","author":"Migayron","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"7891","key":"doi240069r20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","article-title":"Anatomically distinct fibroblast subsets determine skin autoimmune patterns.","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"issue":"16","key":"doi240069r21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo.","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"doi240069r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"doi240069r23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial.","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi240069r24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaci.2023.09.021","article-title":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo.","volume":"153","author":"Guttman-Yassky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi240069r25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/phpp.12749","article-title":"Efficacy of narrow band UVB with or without OMP in stabilization of vitiligo activity in skin photo-types (III-V): a double-blind, randomized, placebo-controlled, prospective, multicenter study.","volume":"38","author":"Esmat","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"doi240069r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107784","article-title":"A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancer.","volume":"222","author":"Vieyra-Garcia","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"3","key":"doi240069r27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy.","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi240069r28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi240069r29","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","article-title":"Addition of narrow-band ultraviolet light B (UVB) phototherapy to ruxolitinib cream in patients with vitiligo.","volume":"142","author":"Pandya","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi240069r30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/bjc.2011.235","article-title":"Designing phase II trials in cancer: a systematic review and guidance.","volume":"105","author":"Brown","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"doi240069r31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2007.09.011","article-title":"Recommended changes to oncology clinical trial design: revolution or evolution?","volume":"44","author":"Ratain","year":"2008","journal-title":"Eur J Cancer"},{"issue":"6","key":"doi240069r32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","article-title":"Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.","volume":"140","author":"Hamzavi","year":"2004","journal-title":"Arch Dermatol"},{"issue":"5","key":"doi240069r33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","article-title":"Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative.","volume":"136","author":"van Geel","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi240069r34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bjd.18950","article-title":"Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).","volume":"183","author":"van Geel","year":"2020","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi240069r35","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","article-title":"Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI).","volume":"12","author":"Kitchen","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi240069r36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus.","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"doi240069r37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.17013","article-title":"International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation.","volume":"180","author":"Eleftheriadou","year":"2019","journal-title":"Br J Dermatol"},{"key":"doi240069r38","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/750342","article-title":"Disease severity indexes and treatment evaluation criteria in vitiligo.","volume":"2011","author":"Kawakami","year":"2011","journal-title":"Dermatol Res Pract"},{"issue":"9","key":"doi240069r39","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/jid.2011.138","article-title":"Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life.","volume":"131","author":"Prinsen","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi240069r40","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2019.02.008","article-title":"Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs).","volume":"81","author":"Ezzedine","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi240069r41","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of vitiligo with oral baricitinib.","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas J Dermatol"},{"key":"doi240069r42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy.","volume":"16","author":"Li","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10244","key":"doi240069r43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"doi240069r44","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial.","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi240069r45","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2161812","article-title":"Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.","volume":"34","author":"Bieber","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"18","key":"doi240069r46","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata.","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"doi240069r47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase iii trials (BRAVE-AA1 and BRAVE-AA2).","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2829424\/jamadermatology_seneschal_2025_oi_240069_1744811602.60937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:01:05Z","timestamp":1744815665000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2829424"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5737","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}